In addition, we found that CTLA4 was markedly correlated with multiple immune checkpoints, which suggested that ccRCC patients with high expressed CTLA4 may benefit more from immune checkpoint blockade combined therapy. Here, CTLA4 is linked to nonpapillary renal cell carcinoma.